6617.Two
6617.TWO is a biotechnology and medical research company operating in the healthcare sector, primarily generating revenue through pharmaceuticals and medical research activities.
Business. 6617.TWO is a biotechnology and medical research company operating in the healthcare sector, primarily generating revenue through pharmaceuticals and medical research activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
6617.TWO is a biotechnology and medical research company operating in the healthcare sector, primarily generating revenue through pharmaceuticals and medical research activities.
The company maintains a strong liquidity position, with a current ratio of 10.36, indicating that it has significantly more current assets than current liabilities. It holds cash and equivalents of 506.41 million TWD, which is a substantial buffer against short-term obligations. However, the company is experiencing negative operating and free cash flows, with operating cash flow at -135.75 million TWD and free cash flow at -112.38 million TWD.
Profitability metrics are concerning, with a return on equity of -4.51% and a return on assets of -4.08%, both significantly below the industry median for biotechnology firms. The company reported a net loss of 114.13 million TWD and an operating loss of 207.29 million TWD, indicating a challenging operating environment.
The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic breakdown provided. This lack of diversification may expose the company to higher operational and market risks if its primary product or service faces regulatory or competitive challenges.
Looking ahead, the company is expected to continue facing financial headwinds, with no significant revenue growth indicated in the outlook. The capital expenditure of -2.46 million TWD suggests minimal investment in new projects or infrastructure, which may limit future growth potential.
Risk factors include the company's negative cash flows and low profitability, which could impact its ability to fund operations and invest in R&D. The dilution risk is currently low, with no immediate filing-based dilution flags detected. However, the company's reliance on a single revenue stream and its current financial performance may increase the likelihood of future dilution if capital raising is required.
Recent filings and transcripts do not indicate any major events or strategic shifts that would significantly alter the company's trajectory. The company remains in a development phase, with ongoing efforts to improve its financial performance and operational efficiency.
- The company has a strong liquidity position but is experiencing negative operating and free cash flows.
- Profitability metrics are significantly below industry medians, with a return on equity of -4.51% and a return on assets of -4.08%.
- Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company is expected to continue facing financial challenges, with no significant revenue growth anticipated.
- Dilution risk is currently low, but the company's financial performance may necessitate capital raising in the future.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 6617.TWO Market data — financials · 2026-05-27